AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15620767 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed Coronectomy
Number of subjects: 128
Study 15620767 — intervention group
Group type: COMPARATOR
Intervention: Extraction, Successful Coronectomy, Failed Coronectomy
Number of subjects: 128
Study 12823122 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on EuroPharm‐Forum Guidelines, provided only to the intervention group
Number of subjects: 119
Study 12823122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 119
Study 12823122 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 119
Study 10826131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of cyanamide
Number of subjects: 0
Study 10826131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of cyanamide at 0.3 mg/kg
Number of subjects: 0
Study 10826131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of cyanamide at 1.0 mg/kg
Number of subjects: 0
Study 10826131 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of cyanamide at 1.5 mg/kg
Number of subjects: 0
Study 8953341 — intervention group
Group type: EXPERIMENTAL
Intervention: Female intercollegiate athletes
Number of subjects: 0
Study 8953341 — intervention group
Group type: COMPARATOR
Intervention: Control group of nonathletic subjects
Number of subjects: 0
Study 8953341 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean sports
Number of subjects: 0
Study 8953341 — intervention group
Group type: EXPERIMENTAL
Intervention: Other sports
Number of subjects: 0
Study 8953341 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 0
Study 8953341 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 1834045 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasil
Number of subjects: 20
Study 1834045 — intervention group
Group type: EXPERIMENTAL
Intervention: Diane
Number of subjects: 20
Study 6984828 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine, administered as a series of four weekly intradermal injections.
Number of subjects: 44
Study 31782747 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed physical activity for five months
Number of subjects: 84
Study 31782747 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of care
Number of subjects: 84
Study 31782747 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 84
Study 31782747 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and insulin levels correlation
Number of subjects: 84
Study 30551317 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum intervention (participants listened to an interview with a person with schizophrenia who endorsed a continuum view)
Number of subjects: 135
Study 30551317 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum intervention (participants listened to an interview with a person with schizophrenia who did not verbally broach issues of similarity to 'normal' people)
Number of subjects: 135
Study 30551317 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum intervention (participants read a bogus research article that attested to a continuum view)
Number of subjects: 135
Study 30551317 — intervention group
Group type: COMPARATOR
Intervention: Control (participants read a bogus research article that was agnostic with respect to the continuum/categorical distinction)
Number of subjects: 135
Study 30551317 — intervention group
Group type: COMPARATOR
Intervention: Control (participants read a bogus research article that attested to a categorical view)
Number of subjects: 135
Study 27486985 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT alone
Number of subjects: 0
Study 27486985 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of Cb with SIT
Number of subjects: 0
Study 25280441 — intervention group
Group type: EXPERIMENTAL
Intervention: GNB3 C825T polymorphism T-carriers (CT/TT)
Number of subjects: 111
Study 25280441 — intervention group
Group type: COMPARATOR
Intervention: GNB3 C825T polymorphism homozygous CC group
Number of subjects: 111
Study 22124679 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable 2-channel peroneal nerve stimulator
Number of subjects: 23
Study 22124679 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking device
Number of subjects: 23
Study 20651476 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 53
Study 20651476 — intervention group
Group type: COMPARATOR
Intervention: Traditional methods of procedural teaching
Number of subjects: 53
Study 16805120 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 30
Study 16805120 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 30
Study 14566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane (60 mg for 8 days)
Number of subjects: 16
Study 14566442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched for 8 days)
Number of subjects: 16
Study 10991864 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg of VGC per os (p.o.) once a day (q.d.)
Number of subjects: 28
Study 10991864 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg of VGC p.o. q.d.
Number of subjects: 28
Study 10991864 — intervention group
Group type: COMPARATOR
Intervention: 1 g of oral GCV three times a day
Number of subjects: 28
Study 10991864 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of intravenous (i.v.) GCV per kg of body weight q.d.
Number of subjects: 28
Study 9236310 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral ritodrine from the 25th to the end of the 37th week of gestation
Number of subjects: 189
Study 9236310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization from the 28th to the 32nd week of gestation
Number of subjects: 189
Study 9236310 — intervention group
Group type: COMPARATOR
Intervention: Outpatient management (control group)
Number of subjects: 189
Study 1358620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine (20 mg)
Number of subjects: 12
Study 1358620 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.8 g.kg‐1)
Number of subjects: 12
Study 1358620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine with ethanol
Number of subjects: 12
Study 6202000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 192
Study 6202000 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 192
Study 6202000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and furosemide
Number of subjects: 192
Study 30817250 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX plus Pegylated Recombinant Human Hyaluronidase (PEGPH20) at a dosage of 3 µg/kg every 2 weeks
Number of subjects: 138
Study 30817250 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX alone (Control)
Number of subjects: 138
Study 28531768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosa Damascena oil (drops)
Number of subjects: 50
Study 28531768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25441055 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving psychotherapy
Number of subjects: 46
Study 25441055 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 46
Study 23218058 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) training intervention
Number of subjects: 71
Study 23218058 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 71
Study 21774293 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (TBI) with motivational interviewing and supportive techniques, individual weekly therapy sessions of 20 to 30 minutes via telephone for six weeks.
Number of subjects: 60
Study 21774293 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (TBI)
Number of subjects: 60
Study 21774293 — intervention group
Group type: COMPARATOR
Intervention: Control group (received mail concerning health promotion)
Number of subjects: 60
Study 19547854 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy in the postoperative recovery room and subsequently in the infirmary
Number of subjects: 0
Study 19547854 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy in the infirmary exclusively
Number of subjects: 0
Study 16752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations in the third trimester (9.9+/‐1.4 microg/ml) compared to pregravid condition (13.5+/‐1.8 microg/ml)
Number of subjects: 0
Study 16752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion in pregravid women
Number of subjects: 0
Study 16752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-mediated changes in adiponectin
Number of subjects: 0
Study 16752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between adiponectin and insulin sensitivity
Number of subjects: 0
Study 15180608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 75
Study 15180608 — intervention group
Group type: COMPARATOR
Intervention: Control (no local anaesthetic)
Number of subjects: 75
Study 11291551 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg three times daily for 10 days
Number of subjects: 148
Study 11291551 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir 800 mg five times daily for 10 days
Number of subjects: 148
Study 11291551 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 148
Study 9725757 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg)
Number of subjects: 30
Study 9725757 — intervention group
Group type: EXPERIMENTAL
Intervention: oxazepam (30 mg)
Number of subjects: 30
Study 9725757 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 9725757 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (2 mg) and oxazepam (30 mg)
Number of subjects: 30
Study 7986772 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 11
Study 7986772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined amphetamine (0.3 mg/kg) with haloperidol (2 mg)
Number of subjects: 11
Study 7986772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7986772 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine (0.3 mg/kg)
Number of subjects: 11
Study 2567218 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 35
Study 2567218 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 35
Study 5296380 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment with isoniazid plus PAS
Number of subjects: 193
Study 5296380 — intervention group
Group type: COMPARATOR
Intervention: Sanatorium treatment with isoniazid plus PAS
Number of subjects: 193
Study 29625822 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture at 36.5°C
Number of subjects: 412
Study 29625822 — intervention group
Group type: COMPARATOR
Intervention: Culture at 37°C
Number of subjects: 412
Study 27930453 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20
Study 27930453 — intervention group
Group type: COMPARATOR
Intervention: Local muscle vibration (LMV)
Number of subjects: 20
Study 27930453 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 20
Study 26502523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressing micro-regulating group
Number of subjects: 136
Study 26502523 — intervention group
Group type: COMPARATOR
Intervention: Traditional massage group
Number of subjects: 136
Study 23064079 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (75 mg twice a day for 7 days)
Number of subjects: 10
Study 23064079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21535995 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5-10 mg/d
Number of subjects: 451
Study 21535995 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg/d
Number of subjects: 451
Study 21535995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 18437472 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic assisted distal gastrectomy (LADG)
Number of subjects: 162
Study 18437472 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 162
Study 17052415 — intervention group
Group type: EXPERIMENTAL
Intervention: Armoured laryngeal mask airway
Number of subjects: 100
Study 17052415 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube
Number of subjects: 100
Study 12838221 — intervention group
Group type: EXPERIMENTAL
Intervention: 10F polyurethane stent
Number of subjects: 120
Study 12838221 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic hydromer‐coated polyurethane stent
Number of subjects: 120
Study 12838221 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon Tannenbaum stent
Number of subjects: 120
Study 11321640 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructive cognitive process
Number of subjects: 10
Study 11321640 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval process
Number of subjects: 10
Study 11321640 — intervention group
Group type: EXPERIMENTAL
Intervention: Judged error rates
Number of subjects: 10
Study 11321640 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between judged and actual error rates
Number of subjects: 10
Study 9256559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57
Study 9256559 — intervention group
Group type: COMPARATOR
Intervention: Psychodynamic‐interpersonal therapy
Number of subjects: 57
Study 9256559 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact sessions
Number of subjects: 57
Study 9256559 — intervention group
Group type: COMPARATOR
Intervention: Low-impact sessions
Number of subjects: 57
Study 9256559 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' ratings of session depth and smoothness
Number of subjects: 57
Study 9256559 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients' ratings of mood
Number of subjects: 57
Study 8290661 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150-200 mg/day
Number of subjects: 312
Study 8290661 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 50-75 mg/day
Number of subjects: 312
Study 8290661 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg/day
Number of subjects: 312
Study 8290661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 3069486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg daily)
Number of subjects: 20
Study 3069486 — intervention group
Group type: COMPARATOR
Intervention: Control (no Nifedipine)
Number of subjects: 20
Study 3069486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually)
Number of subjects: 20
Study 29202886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 2609
Study 29202886 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 2609
Study 29202886 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither therapy
Number of subjects: 2609
Study 29202886 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge home
Number of subjects: 2609
Study 29202886 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic on arrival
Number of subjects: 2609
Study 29202886 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with rhythm control
Number of subjects: 2609
Study 28166751 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based educational intervention providing specific information about guideline recommendations for surveillance colonoscopy.
Number of subjects: 767
Study 28166751 — intervention group
Group type: COMPARATOR
Intervention: Generic pamphlet on colorectal cancer treatment (Control group).
Number of subjects: 767
Study 28166751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to new guidelines (post hoc analysis).
Number of subjects: 767
Study 28166751 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to old guidelines (post hoc analysis).
Number of subjects: 767
Study 24467843 — intervention group
Group type: EXPERIMENTAL
Intervention: High velocity, low amplitude (HVLA)
Number of subjects: 51
Study 24467843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization (Mob)
Number of subjects: 51
Study 24467843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained natural apophyseal glide (SNAG)
Number of subjects: 51
Study 22545990 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed loaded exercise programme
Number of subjects: 210
Study 22545990 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic-based physiotherapy
Number of subjects: 210
Study 19891671 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 32
Study 19891671 — intervention group
Group type: COMPARATOR
Intervention: classic laryngeal mask airway
Number of subjects: 32
Study 17637601 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice
Number of subjects: 14
Study 17637601 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh fruit
Number of subjects: 14
Study 17637601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried fruit
Number of subjects: 14
Study 16245914 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection
Number of subjects: 65
Study 16245914 — intervention group
Group type: COMPARATOR
Intervention: Control group (western medicine only)
Number of subjects: 65
Study 12044376 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous fluids in accordance with hospital practice (> or = 3 L water and 154 mmol sodium per day)
Number of subjects: 20
Study 12044376 — intervention group
Group type: COMPARATOR
Intervention: Restricted intake (< or = 2 L water and 77 mmol sodium per day)
Number of subjects: 20
Study 12044376 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intravenous fluids in accordance with hospital practice
Number of subjects: 20
Study 12044376 — intervention group
Group type: COMPARATOR
Intervention: Restricted intake
Number of subjects: 20
Study 9862566 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked infiltration of dendritic cells (DCs)
Number of subjects: 0
Study 9862566 — intervention group
Group type: COMPARATOR
Intervention: Slight infiltration of dendritic cells (DCs)
Number of subjects: 0
Study 9862566 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration by dendritic cells (DCs)
Number of subjects: 0
Study 9862566 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of vascular endothelial growth factor (VEGF)
Number of subjects: 0
Study 7616473 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated polyglactin 910
Number of subjects: 236
Study 7616473 — intervention group
Group type: COMPARATOR
Intervention: Traditional interrupted, monofilament, non-absorbable suturing (Control)
Number of subjects: 236
Study 2665554 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g/kg alcohol drink on Days 1-4, placebo on Day 5
Number of subjects: 24
Study 2665554 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink on all study Days (1-5)
Number of subjects: 24
Study 2665554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol stimuli
Number of subjects: 24
Study 2665554 — intervention group
Group type: COMPARATOR
Intervention: Water or pepper juice stimuli
Number of subjects: 24
Study 627302 — intervention group
Group type: EXPERIMENTAL
Intervention: Floctafenine (Idarac) 200 mg four times daily
Number of subjects: 0
Study 627302 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 200 mg four times daily
Number of subjects: 0
Study 31812785 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based learning (SBL)
Number of subjects: 70
Study 31812785 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 70
Study 30430592 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week Physical Activity Program
Number of subjects: 0
Study 28454795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combo sirolimus‐eluting stent
Number of subjects: 572
Study 28454795 — intervention group
Group type: COMPARATOR
Intervention: Best-in-class contemporary everolimus‐eluting stent
Number of subjects: 572
Study 28454795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve assessment
Number of subjects: 572
Study 28454795 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging
Number of subjects: 572
Study 28454795 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial human antimurine antibody assessments
Number of subjects: 572
Study 25841317 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL)
Number of subjects: 13
Study 25841317 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (non-CXL)
Number of subjects: 13
Study 23544117 — intervention group
Group type: EXPERIMENTAL
Intervention: Music education intervention (n=114)
Number of subjects: 235
Study 23544117 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=121)
Number of subjects: 235
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Shochu with meal (460 kcal)
Number of subjects: 35
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Shochu without meal
Number of subjects: 35
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer with meal (460 kcal)
Number of subjects: 35
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer without meal
Number of subjects: 35
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Shochu in prandial condition
Number of subjects: 35
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Shochu in fasted condition
Number of subjects: 35
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer in prandial condition
Number of subjects: 35
Study 21861333 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer in fasted condition
Number of subjects: 35
Study 19571762 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (18 ml of 0.25% bupivacaine)
Number of subjects: 90
Study 19571762 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 90